We have moved to new location, Please click on contact us  
Home  >  News
you can get e-magazine links on WhatsApp. Click here
Biotechnology + Font Resize -

Health Ministry calls reports against approval of Covaxin as misleading

Our Bureau, New Delhi
Thursday, November 17, 2022, 15:40 Hrs  [IST]

The Ministry of Health and Family Welfare has stated that the media reports claiming that Bharat Biotech, manufacturer of the indigenous Covid-19 vaccine Covaxin, “had to skip certain processes” and “speed” up clinical trials due to political pressure as completely misleading, fallacious and ill-informed.

Reports published in some of the publications recently alleged that “the regulators endorsed the vaccine despite discrepancies in the number of clinical trial participants,” among other allegations related to the irregularities in the approval.

Responding to the reports, the Ministry of Health said, “There have been media reports claiming that Bharat Biotech, manufacturer of the indigenous COVID-19 vaccine – Covaxin, ‘had to skip certain processes’ and ‘speed’ up clinical trials due to political pressure. The reports further claim that there were several irregularities in the three phases of the clinical trials conducted for the vaccine. These media reports are completely misleading, fallacious and ill-informed.”

It also clarified that Government of India and the national regulator Central Drugs Standard Control Organisation (CDSCO) have followed a scientific approach and prescribed norms in approving COVID-19 vaccines for emergency use authorization.

The Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) met on 1st and 2nd January, 2021 and after due deliberations made recommendations in respect of proposal for Restricted Emergency Approval of COVID-19 virus vaccine of Bharat Biotech.

Before Covaxin was approved for restricted emergency use in January 2021, the Subject Expert Committee reviewed the data on safety and immunogenicity of the vaccine and recommended for grant of permission for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains, it said.

“The SEC’s approval for commencement of phase 3 clinical trial of proposed dose of Covaxin was based on scientific data presented by Bharat Biotech and established practices in this regard. Moreover, the purported ‘unscientific changes’ in clinical trials of Covaxin, as claimed in the news reports, were made after submission made by Bharat Biotech  in CDSCO, compliance of due process in CDSCO and with approval from the DGCI,” refuted the statement by the Ministry.

Additionally, later on, based on further submission made by Bharat Biotech and assessment of interim efficacy and safety data by SEC of CDSCO, the condition of administration of COVID-19 vaccine in ‘clinical trial mode’ was removed on March 11, 2021.

“Authorization to COVID-19 vaccines including Covaxin for restricted use in emergency situation with various conditions and restrictions were granted by the national regulator only on the recommendations of the Subject Expert Committee of CDSCO. The Subject Expert Committee consists of domain knowledge experts from the fields of pulmonology, immunology, microbiology, pharmacology, paediatrics, internal medicine, etc.”, it added.

It may be noted that the criticisms against the fast-tracked approval to the vaccine has been raised by various activists right from the approval of the vaccine for administration, and it also got emphasised following the World Health Organisation (WHO) suspending the supply of Covaxin in April, 2022, after the WHO inspection identified some Good Manufacturing Practice (GMP) related deficiencies in the product.

The WHO listed Covaxin against Covid-19 for emergency use on November 3, 2021.


* Name :     
* Email :    
  Website :  
India Lab Expo
Copyright © 2016 Saffron Media Pvt. Ltd |